cipramil (celexa) stories,, lundbeck, Newspaper and internet articles, psychiatry

STAR*D raises its ugly head again.

STAR*D raises its ugly head again.

I have briefly mentioned the latest LawSuit involving allegations of kickbacks and bribes committed by Forest Labs. For people who are not familiar with the pharmaceutical industry, let me explain, Forest are Lundbeck’s partner in crime, who market Citalopram and Escitalopram to the American public.

Forest have the dubious reputation of peddling their medication (off-label) to children. They previously paid 313 million to settle criminal and civil complaints for illegally promoted Citalopram/Celexa/Cipramil for use in children. This was despite a very clear black box warning that this drug could induce sucidality in young people (Under 25’s) and that the same drug was not licenced for under 18’s for that reason. NY Times.

The latest whistleblower suit unsealed in Maryland federal court last month, claim that Forest paid kickbacks and bribes to the main author of the STAR*D drug study, Dr. A. John Rush. The suit alleges that Dr Rush of the University of Texas was paid these bribes so that he would rig the STAR*D study in favor of the company’s drug Celexa. The STAR*D study (Sequenced Treatment Alternatives to Relieve Depression) was conducted over 6 years, was funded by NIMH and cost $35 million; that’s not including Forest’s bribary stash account.

Robert Whitaker, whose book “Anatomy of an Epidemic” won an award for best investigative journalism book of 2010, has been campaigning for a full Investigation into the STAR*D scandal. Here.

STAR*D: What Have We Learned? In 2007 the American Journal of Psychiatry published a paper by Dr Rush entitled “STAR*D: What Have We Learned?” Link. In the last paragraph he says “Finally, on a personal note, large efforts like STAR*D are the ultimate exercise in “delayed gratification.” I bet it was.


His declared conflicts of interest:

Dr. Rush has served as an advisor, consultant, or speaker for or received research support from Advanced Neuromodulation Systems, Inc.; Best Practice Project Management, Inc.; Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly & Company; Forest Pharmaceuticals, Inc.; Gerson Lehman Group; GlaxoSmithKline; Healthcare Technology Systems, Inc.; Jazz Pharmaceuticals; Merck & Co., Inc.; the National Institute of Mental Health; Neuronetics; Ono Pharmaceutical; Organon USA Inc.; Personality Disorder Research Corp.; Pfizer Inc.; the Robert Wood Johnson Foundation; the Stanley Medical Research Institute; the Urban Institute; and Wyeth-Ayerst Laboratories Inc. He has equity holdings in Pfizer Inc and receives royalty/patent income from Guilford Publications and Healthcare Technology Systems, Inc. Dr. Freedman reviewed this editorial and found no evidence of influence from these relationships. (Really Dr Freedman?)

STAR*D: What Have We Learned? Well I for one have learned that Celexa can cause extremely violent deaths. I have learned that Forest labs and Lundbeck are aware that their drugs can cause suicide and homicide. I have also learned that kickbacks and bribes are an integral part of their operation. Fancy doing a paper on that Dr. Rush?

1 thought on “STAR*D raises its ugly head again.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s